

RECEIVED
CENTRAL FAX CENTER

JUL 01 2009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:)	Docket No.:	4354-110
Applicants:)	Conf. No.:	4322
CABANA, Bernard E., et)		
al.)		
Application No.:)	Art Unit:	1614
10/668,792)		
Date Filed:)	Examiner:	Spivack, Phyllis G.
September 23, 2003)		
Title:)	Customer	
RIFALAZIL)	No.:	23448
COMPOSITIONS AND)		
THERAPEUTIC)		
REGIMENS)		

FACSIMILE TRANSMISSION CERTIFICATEATTN: Examiner Spivack

Fax No. (571) 273-8300

I hereby certify that this document, along with any enclosures identified herein, is being filed in the United States Patent and Trademark Office, via facsimile transmission addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, and transmitted on the date specified below, to United States Patent and Trademark Office facsimile transmission number (571)273-8300.

14
Number of Pages

Kate Post

July 1, 2009

Date

RESPONSE TO OFFICE ACTION IN U.S. PATENT APPLICATION NO. 10/668,792

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The following responds to the Office Action mailed in connection with the above-identified application on February 5, 2009.

07/02/2009 JVONG1 00000032 10668792

01 FC:2252

245.00 0P

RECEIVED
CENTRAL FAX CENTER

05:30:29 p.m. 07-01-2009

JUL 01 2009

4354-110

The time for responding to the February 5, 2009 Office Action without extension was set at three months, or May 5, 2009. Applicants hereby request a two month extension of time under 37 CFR §1.136 to extend the deadline for response to July 5, 2009. Payment of the \$245.00 small entity fee specified in 37 CFR § 1.17(a) is authorized in the enclosed Credit Card Payment Form PTO-2038. Authorization also is hereby given to charge the amount of any additional fee properly payable for the filing and entry of this Response, to Deposit Account No. 08-3284 of Intellectual Property/Technology Law.

Please amend the claims of the above-identified patent application as set out in **Section I (Amendments to the Claims)**, beginning on page 3 hereof.

Remarks concerning the amendments to the claims and the substance of the Office Action are set out in **Section II (Remarks)** hereof.